Importance COVID-19 is associated with clinically significant symptoms despite resolution
of the acute infection (ie, post-COVID-19 syndrome). Fatigue and cognitive impairment are …

Following recovery from COVID-19, an increasing proportion of individuals have reported the
persistence and/or new onset of symptoms which collectively have been identified as post-…

Ketamine is a promising therapeutic option in treatment-resistant depression (TRD). The
acute efficacy of ketamine in TRD has been demonstrated in replicated randomised-controlled …

Empirical evidence addressing the association between SARS-CoV-2 vaccination and long
COVID would guide public health priorities and inform personal health decisions. Herein, …

Background A considerable proportion of individuals report persistent, debilitating and
disparate symptoms despite resolution of acute COVID-19 infection (ie long COVID). Numerous …

Multiple lines of evidence have implicated brain-derived neurotrophic factor (BDNF) in
treatment-resistant depression (TRD). The aim of this synthesis was to determine the impact of …

While ketamine has been used clinically over the past decades, it has only been recently
shown to be a promising therapy for treatment-resistant depression (TRD). However, ketamine …

Objectives: Ketamine is a glutamate N-methyl-D-aspartate receptor antagonist that can be
used to treat major depressive disorder by single or repeated infusions. However, the …

… panel Isak Joneborg a b , Yena Lee b c d , Joshua D. Di Vincenzo b c d , Felicia Ceban b
d , Shakila Meshkat d , Leanna MW Lui d g , Farhan Fancy c d g , Joshua D. Rosenblat b c …

Suicide accounts for approximately 800,000 deaths per year globally. Previous research
has shown that intranasal esketamine and intravenous ketamine can rapidly decrease the …